06681 腦動極光－Ｂ
BRAINAURORA-B
BRAINAURORA-B
| Listing Date | 2025/01/08 |
| Listing Price | 3.220 |
Subscription Result
- Subscription Rate11.39x
- Guarantee One Lot Size9 lot
- One Lot Success Rate50.01%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
BrainAurora Medical Technology Limited is a commercial stage company, founded in 2012. The Group’s product pipeline covers both the assessment and intervention of a broad range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, psychiatric disorders and child development deficiencies, among others.
--
The Group’s core product, the Brain Function Information Management Platform Software System, has been commercialized for eight indications from four major types of cognitive impairment and is under development for several other cognitive impairment indications as of December 21, 2024. The Group had three other products that had received regulatory approval in China, the Basic Cognitive Ability Testing Software (the “BCAT”), the Cognitive Ability Supplemental Screening and Assessment Software (the “SAS”) and the Dyslexia Supplemental Screening and Assessment Software (the “DSS”) and one other product that had received regulatory approval in the EU, the Cognitive Impairment Treatment Software.
--
The Group is also the first organizer of a project initiated by the NHC, according to Frost & Sullivan, under which it is tasked with helping hospitals to establish cognitive centers in over 2,100 public hospitals across China and promoting the development of cognitive impairment DTx market in China. The Group have a 25.0% market share in China’s cognitive impairment DTx market and 91.6% market share in China’s medical-grade cognitive impairment DTx market in terms of revenue in 2023.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 1000 |
GLOBAL OFFERING
| No. of Offer Shares | 181.11M shares |
| No. of International Offer Shares | 163.00M shares |
| No. of HK Offer Shares | 18.11M shares |
| Offer Price | $3.22 |
| Stock Code | 6681 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited, SPDB International Capital Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, SPDB International Capital Limited, CMB International Capital Limited, Fosun International Securities Limited, Tiger Brokers (HK) Global Limited, GF Securities (Hong Kong) Brokerage Limited, CCB International Capital Limited, BOCI Asia Limited, China Everbright Securities (HK) Limited, ABCI Securities Company Limited, CMBC Securities Company Limited, China Industrial Securities International Capital Limited, Haitong International Securities Company Limited |
TIME TABLE
| Application Period | Dec 30 (Mon) - noon, Jan 03 (Fri) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Jan 07 (Tue) |
| Result Announcement Date | On or before Jan 07 (Tue) |
| Result Announcement Date | On or before Jan 08 (Wed) |
| Dealings in Shares commence on | Jan 08, 2025. (Wed) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $3.22 |
| Capitalization | 4.08B |
| NAV / share ($) | $0.09 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 3.22, the net proceeds raised would be HKD 501.30M, of which |
| 40% : Conducting further research and development activities, advancing clinical trials for more indications, and advancing selling and distribution activities of Core Product, the System |
| 16.5% : Helping establish new cognitive centers for more hospitals across China |
| 15% : Strengthening capabilities in AI and related technologies |
| 5% : Accelerating the research, development and commercialization of other product candidates in and beyond current product pipeline |
| 15% : Used for brain science and DTx research centers in collaboration with academic institutions and hospitals |
| 8.5% : Working capital |
IPO NEWS
| 08/01/2025 16:08 |
| {New Stock}BRAINAURORA-B(06681) ends up 3.42% at HK$3.33 |
| 08/01/2025 09:21 |
| {New Stock}BRAINAURORA-B(06681) opens flat at HK$3.22 |
| 07/01/2025 18:35 |
| {New Stock}BRAINAURORA-B ends down 0.31% on grey market |
| 07/01/2025 16:20 |
| {New Stock}BRAINAURORA-B up 3.42% at HK$3.33 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).